Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 7, 2025 • 10:00 PM ET

Date/Time Source News Release
05/20/2025 05:26 AM EDT PR Newswire CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
05/16/2025 06:36 PM EDT Business Wire CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
05/13/2025 04:05 PM EDT GlobeNewswire Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
05/13/2025 09:00 AM EDT GlobeNewswire Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
05/06/2025 09:15 AM EDT GlobeNewswire Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
05/05/2025 08:00 AM EDT GlobeNewswire Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
04/01/2025 09:00 AM EDT GlobeNewswire Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
03/19/2025 04:05 PM EDT GlobeNewswire Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
03/17/2025 09:25 AM EDT GlobeNewswire Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
03/11/2025 09:00 AM EDT GlobeNewswire Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Page

Additional News

As of June 7, 2025 • 10:00 PM ET

Date/Time Source News Release
06/03/2025 10:00 AM EDT ACCESS Newswire IA Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
06/02/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation
06/01/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect
05/30/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out
05/29/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation
05/28/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation
05/27/2025 10:00 AM EDT ACCESS Newswire IA Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
05/26/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect
05/25/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation
05/23/2025 10:00 AM EDT ACCESS Newswire IA Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Investors to Inquire about Securities Investigation
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.